4CPS-024 Efficacy, safety and acceptance of treatment with alirocumab or evolocumab in patients with dyslipidaemia

BackgroundAlirocumab and evolocumab are two monoclonal antibodies proproteinconvertasesubtilisin/kexin type 9 inhibitors (iPCSK9) approved for the treatment of hypercholesterolaemia.PurposeEvaluation of the efficacy, safety and patient acceptance of treatment with iPCSK9 in a cohort of patients with dyslipidaemia.Material and methodsRetrospective observational study performed in a university hospital. Included patients started with iPCSK9 therapy from September 2016 to June 2018.Data collected: demographic; iPCSK9 dose; prevention; indication; cardiovascular risk factors (CVRF) (excluding dyslipidaemia), cardiovascular risk (CVR) (by ESC 2016 guidelines); and statin intolerance.At baseline (pre) and 6–12 weeks after starting treatment (post), LDL value and concomitant lipid lowering agents (LLA) were collected.Additionally, reported adverse events and patient treatment were evaluated through a validated survey1 during the pharmaceutical visit.Statistics: Categorical variables: n (%), Fisher’s exact test.Quantitative variables: mean ±SD/median(rank), Mann–Whitney U test.ResultsAbstract 4CPS-024 Table 1 Baseline Alirocumab (n= 48) Evolocumab (n= 10) P-value Male29 (60.4%)9 (90.0%)Age62.6±8.655.8±8.8Initial dose:75 mg/2 weeks40 (83.3%)-Secondary prevention38 (79.2%)10 (100.0%)IndicationPolygenic-hypercholesterolaemia31 (64.6%)8 (80.0%)Familial-hypercholesterolaemia14 (29.2%)1 (10.0%)Other3 (6.3%)1 (10.0%)CVRFNone13 (27.1%)1 (10.0%)117 (35.4%)2 (20.0%)≥218 (37.5%)7 (70.0%)High-risk CVR38 (79.2%)10 (100.0%)Statin intolerance25 (52.1%)4 (40.0%)Pre LLA45 (93.7%)9 (90.0%) LDLLDL (mg/dL)Pre138.5 (92–308)111.5 (92–216)0.067Post59 (17–223)28.5 (4–59)0.002% LDL reduction57.7 (13.2–87.5)75.2 (47.3–97.3)0.015LDL post